Cyclo Therapeutics(US:CYTH)2024-08-14 21:28Financial Performance - The company reported net losses of approximately $5,981,000 and $10,324,000 for the three and six months ended June 30, 2024, compared to net losses of approximately $4,636,000 and $9,644,000 for the same periods in 2023[85]. - Total revenues for the three-month period ended June 30, 2024 increased by 5% to approximately $123,000, while revenues for the six-month period increased by 21% to approximately $326,000 compared to the same periods in 2023[86]. - Sales of Trappsol® HPB decreased by 63% for the three-month period ended June 30, 2024 to approximately $21,000, but increased by 54% for the six-month period to approximately $220,000 compared to the same periods in 2023[86]. - Sales of other Trappsol® products increased by 68% for the three-month period ended June 30, 2024 to approximately $101,000, but decreased by 10% for the six-month period to approximately $104,000 compared to the same periods in 2023[86]. - The three largest customers accounted for 89% of sales during the six months ended June 30, 2024, with the largest customer accounting for 33% of sales[88]. Expenses - Cost of products sold for the three-month period ended June 30, 2024 decreased by 35% to approximately $13,000, and for the six-month period decreased by 17% to approximately $25,000 compared to the same periods in 2023[89]. - Personnel expenses increased by 17% to approximately $916,000 for the three months ended June 30, 2024, and increased by 3% to approximately $1,738,000 for the six months ended June 30, 2024 compared to the same periods in 2023[92]. - Research and development expenses increased by 10% to approximately $3,492,000 for the three months ended June 30, 2024, but decreased by 4% to approximately $6,337,000 for the six months ended June 30, 2024 compared to the same periods in 2023[93]. - Office and other expenses increased by 204% to approximately $829,000 for the three months ended June 30, 2024, and increased by 210% to approximately $1,721,000 for the six months ended June 30, 2024 compared to the same periods in 2023[94]. Cash Flow and Capital - Cash decreased to approximately $1,122,000 as of June 30, 2024, compared to approximately $9,247,000 as of December 31, 2023[96]. - Negative working capital was approximately $5,378,000 as of June 30, 2024, compared to positive working capital of approximately $3,850,000 at December 31, 2023[96]. - Net cash used in operating activities was approximately $10,030,000 for the six months ended June 30, 2024, compared to approximately $7,849,000 for the same period in 2023, reflecting increased clinical trial activities[100]. - Net cash provided by financing activities was approximately $1,905,000 for the six months ended June 30, 2024, down from approximately $7,147,000 for the same period in 2023[100]. - The company will need to raise additional capital to support ongoing operations and clinical trials, with no guarantee of success[97]. Tax and Valuation - The company has approximately $49,807,000 in net state and federal operating loss carryforwards expiring from 2024 through 2037[99]. - A 100% valuation allowance was provided on the deferred tax asset based on expected future expenses related to clinical trials and development initiatives[99]. Internal Controls and Compliance - Disclosure controls and procedures were not effective as of June 30, 2024, indicating potential issues in financial reporting[103]. - A material weakness in internal controls over the accounting of complex equity instruments was identified, necessitating remediation efforts[103]. - The company had no off-balance sheet arrangements as of June 30, 2024[99]. Research and Development - The company is exploring the use of cyclodextrins in the treatment of Alzheimer's disease, with a Phase II study initiated in 2023 following IND clearance from the FDA[83].